US FDA Proposes New Medtech Fee Categories
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is proposing to create new user fees to pay for de novo classification reviews and pre-submission consultations, among other reforms, as part of the next user fee program (MDUFA IV)1.